Tislelizumab
Tislelizumab is a monoclonal antibody used in the treatment of various types of cancer. It is specifically designed to target and inhibit the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system.
Mechanism of Action[edit]
Tislelizumab works by binding to the PD-1 receptor on T cells, a type of white blood cell that plays a crucial role in the body's immune response. By inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2, tislelizumab enhances the immune system's ability to detect and destroy cancer cells.
Indications[edit]
Tislelizumab is approved for the treatment of several types of cancer, including:
Clinical Trials[edit]
Tislelizumab has undergone extensive clinical trials to evaluate its efficacy and safety. These trials have demonstrated significant anti-tumor activity and manageable safety profiles in patients with various types of cancer.
Side Effects[edit]
Common side effects of tislelizumab include:
Serious side effects may include immune-related adverse events such as pneumonitis, hepatitis, colitis, and endocrinopathies.
Development and Approval[edit]
Tislelizumab was developed by BeiGene, a global biotechnology company. It has received approval from regulatory agencies in several countries for the treatment of specific types of cancer.
See Also[edit]
References[edit]
External Links[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
